Full-Time
Develops therapies for neurodegenerative diseases
$280k - $303k/yr
Senior
Remote in USA
Upload your resume to see how it matches 10 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Alector develops therapies aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's. The company focuses on research and development of new drug candidates by utilizing knowledge from immunology, neurology, and human genetics. Their approach involves conducting early-stage clinical trials to gather specific data about diseases, which helps improve the chances of success for their treatments. Alector generates revenue through partnerships, grants, and future sales of their therapies. What sets Alector apart from competitors is their emphasis on leveraging the body's natural healing processes and their commitment to addressing significant medical needs in the field of neurodegeneration. The company's goal is to create effective treatments that can significantly improve the lives of patients suffering from these conditions.
Company Size
201-500
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
Hybrid Work Options
In another strategy, Alector, in collaboration with GSK, is developing the monoclonal antibody latozinemab (AL001), which works by blocking progranulin degradation to boost its availability.
As part of cost-cutting efforts, Alector is letting go of about 25 people as it focuses on advancing its preclinical and research pipeline.
Alector, Inc. was developing AL002, its TREM2 program asset, to treat patients with early Alzheimer?s disease (AD) in collaboration with AbbVie Biotechnology Ltd. under the Co-Development and Option Agreement, dated as of October 16, 2017, between the parties, as amended on February 13, 2023.
Wellington Management Group LLP invests $639,000 in Alector, Inc. (NASDAQ:ALEC).
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer’s clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer’s fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels